Ventures Spero Therapeutics 6. marts 2020 Spero Therapeutics Announces Closing of Rights Offering Spero Therapeutics 2. marts 2020 Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Acacia Pharma 2. marts 2020 Acacia Pharma Group PLC – Acacia Pharma Group plc: Results for the year ended 31 December 2019 Acacia Pharma 2. marts 2020 Acacia Pharma Group PLC – Acacia Pharma Announces Changes to its Officers and Board of Directors Spero Therapeutics 27. februar 2020 Spero Therapeutics to Present at March Investor Conferences Acacia Pharma 27. februar 2020 Acacia Pharma Group PLC – Acacia Pharma Announces US FDA Approval of BARHEMSYS® (amisulpride) for the Treatment and Prevention of Postoperative Nausea and Vomiting (PONV) Acacia Pharma 27. februar 2020 Acacia Pharma Group PLC – Acacia Pharma to Announce its Results for the Full Year 2019 on 2 March 2020 and Provides Notice of its Annual General Meeting Sanifit 17. februar 2020 First patient dosed in pivotal phase 3 trial of SNF472 in calciphylaxis Spero Therapeutics 11. februar 2020 Spero Therapeutics Announces Commencement of Rights Offering Spero Therapeutics 30. januar 2020 Spero Therapeutics Announces Proposed Rights Offering Sideinddeling Første side « Første Forrige side ‹‹ … Side 2 Side 3 Side 4 Side 5 Nuværende side 6 Side 7 Side 8 Side 9 Side 10 … Næste side ›› Sidste side Sidste »
